DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vicriviroc
Vicriviroc
Download Article PDF/Slides
Microbicides 2008
Semen-Mediated Enhancement of HIV-1 Infection Markedly Impairs the Antiviral Efficacy of Microbicides
What Lessons Can We Learn from 20 Years of Chemokine T D Di ? Receptor
A Novel Small Molecule CCR5 Inhibitor Active Against R5-Tropic HIV-1S
HIV - Cancer ®
Leronlimab, a Humanized Monoclonal Antibody to CCR5, Blocks Breast Cancer Metastasis and Enhances Cell Death Induced by DNA Dama
Stembook 2018.Pdf
CCR5 Inhibitors and HIV-1 Infection
Repurposing of FDA Approved Drugs
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
CCR5 Inhibitors And
Ccr5 Antagonists in the Treatment of Treatment-Naïve Patients Infected with Ccr5 Tropic Hiv-1
Reduction of CCR5 with Low-Dose Rapamycin Enhances the Antiviral Activity of Vicriviroc Against Both Sensitive and Drug-Resistant HIV-1
Women's Interagency Hiv Study Drug List 1 – By
MTN-027 Phase 1 Safety and Pharmacokinetics Study of MK
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
The COVID-19 Pandemic and Its Impact on the Cardio-Oncology Population
Top View
WO 2017/035230 Al 2 March 2017 (02.03.2017) P O P C T
HIV-1 Entry Inhibition by Small-Molecule CCR5 Antagonists: a Combined Molecular Modeling and Mutant Study Using a High-Throughput Assay
(12) Patent Application Publication (10) Pub. No.: US 2015/0322155A1 Zhao (43) Pub
Anti-HIV Drugs: 25 Compounds Approved Within 25 Years After the Discovery of HIVଝ
In Silico Study of Various Antiviral Drugs, Vitamins, and Natural Substances
Planning for Long-Term Monitoring of Safety in Ccr5 Antagonist Development
Selected Properties of Vicriviroc **In October 2005, Schering Plough
Review Clinical Perspective on Antiretroviral Drug–Drug Interactions with the Non-Nucleoside Reverse Transcriptase Inhibitor Etravirine
New Antiretroviral Therapies and Potential Drug Interactions in HIV
Mechanisms of Ccr5 Agonist/Antagonist Inhibition of Hiv-1
Kidney Disease in HIV: Moving Beyond HIV-Associated Nephropathy
33562549.Pdf
Medical Management of HIV Infection Bartlett.Pdf
HIV-1 Entry and Prospects for Protecting Against Infection
TABLE I: Product and Corporate Developer / Protocol # and IND
WO 2015/196116 Al 23 December 2015 (23.12.2015) P O P C T
Maraviroc Therapy and CCR5 Genotype Laura Dean, MD1 Created: March 18, 2015
Drug Interactions with New and Investigational Antiretrovirals
Anti-Retroviral Drugs for HIV: Old and New
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Combinatorial Anti-HIV Gene Therapy: Using a Multipronged Approach to Reach Beyond HAART
Detergents Enzyme Inhibitors Immunosuppressants Ionophores Molecular Biology Tools Protein Purification Reagents Stem Cell Research Tools
Pre-Exposure Prophylaxis (Prep)
HIV - Cancer NASH - Gvhd
The CCL5/CCR5 Axis in Cancer Progression
In-Silico Drug Repurposing for Targeting SARS-Cov-2 Mpro
Tenofovir Alafenamide
Wo2018/191558
Preventive Technologies: Antiretroviral and Vaccine Development
Us 2019 / 0127401 A1
Management of Dyslipidemia Associated with Anti-Retroviral Therapy in HIV/AIDS Patients
2 HIV Antiretroviral Therapy 11
Reduction of CCR5 with Low-Dose Rapamycin Enhances the Antiviral Activity of Vicriviroc Against Both Sensitive and Drug-Resistant HIV-1
Aplaviroc (GSK) Vicriviroc